The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Toxicity of beti-cel in transfusion-dependent β-thalassemia
Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, discusses the side effects induced by treatment with betibeglogene autotemcel (beti-cel) in patients with transfusion-dependent β-thalassemia. Data has shown that beti-cel may impact fertility, and it is therefore important to conduct fertility management prior to treatment. A further follow-up is required to evaluate the potential of insertional mutagenesis and induction of leukemia. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
